COMMUNIQUÉS West-GlobeNewswire

-
FOXO TECHNOLOGIES INC. DESIGNATES NEW SERIES OF PREFERRED STOCK TO BE USED FOR ACQUISITIONS
27/06/2025 -
Turnstone Biologics Corp. Enters into Agreement to be Acquired by XOMA Royalty Corporation for $0.34 in Cash Per Share Plus a Contingent Value Right
27/06/2025 -
HCW Biologics to Showcase Important Updates on IND-Enabling Studies and Preclinical Success of Its Novel Multi-Specific T-Cell Engagers Against Solid Tumors
27/06/2025 -
Allarity Therapeutics Announces Dosing of Second Patient in New Phase 2 Trial of Stenoparib in Advanced Ovarian Cancer
27/06/2025 -
Orphalan Partners with MAP International and the Wilson Disease Association to Provide Life-Changing Medicine to Underserved Communities
27/06/2025 -
Initiation of commercialization of ProNephro AKI (NGAL) for diagnostic use in the US
27/06/2025 -
Achieve Life Sciences Announces Pricing of $45.0 Million Underwritten Public Offering
27/06/2025 -
Kymera Therapeutics Announces Pricing of $250 Million Public Offering
27/06/2025 -
Vivoryon Therapeutics N.V. to Present at Upcoming Investor Conferences
27/06/2025 -
Tilray Medical publie une recherche pionnière sur la pharmacocinétique des formulations de THC et de CBD
27/06/2025 -
Xenon Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
26/06/2025 -
CorMedix Inc. Announces Proposed Public Offering of Common Stock
26/06/2025 -
Aclaris Therapeutics to Participate in the H.C. Wainwright Inflammation & Immunology Virtual Conference
26/06/2025 -
Achieve Life Sciences Announces Submission of NDA to FDA for Cytisinicline as a Treatment of Nicotine Dependence for Smoking Cessation
26/06/2025 -
Achieve Life Sciences Announces Partnership with Omnicom to Execute Integrated, Data-Driven Launch of the First Potential New Treatment for Nicotine Dependence in Nearly Two Decades
26/06/2025 -
Achieve Life Sciences Announces Proposed Underwritten Public Offering
26/06/2025 -
Windtree Advances Lower Cost Manufacturing of PHEXXI, Evofem’s Hormone-Free, On-Demand Prescription Contraceptive Gel
26/06/2025 -
Regeneron to Report Second Quarter 2025 Financial and Operating Results and Host Conference Call and Webcast on August 1, 2025
26/06/2025 -
Basel Medical Obtains Waiver of Lock-Up for Potential Strategic Fund Raising
26/06/2025
Pages